Chandrasekaran L, Seethalakshmi S, Chandrakasan G, Dhar S C
Biological Laboratory, Central Leather Research Institute, Madras, India.
Biochem Med Metab Biol. 1987 Oct;38(2):205-12. doi: 10.1016/0885-4505(87)90081-8.
Male albino rats were given bleomycin subcutaneously (5 mg potency/kg body weight twice a week) for a period of 6 weeks. At this dosage, mortality was found to be nil with marked fibrotic changes. Pulmonary and cutaneous changes at the end of 2, 4, and 6 weeks of treatment were investigated both by light microscopy and analyses of the intra- and extracellular components. Histologically, fibrosis set in as early as 2 weeks of treatment with bleomycin and was pronounced with increasing duration of treatment. Biochemically, total collagen and hexosamine contents of lung and skin increased significantly compared to control toward the end of treatment period. Thus, this animal model can be conveniently used to mimic the human condition and to test effective antifibrotic agents.
雄性白化病大鼠皮下注射博来霉素（5毫克效价/千克体重，每周两次），持续6周。在此剂量下，死亡率为零，但出现了明显的纤维化改变。在治疗2周、4周和6周结束时，通过光学显微镜以及细胞内和细胞外成分分析，对肺部和皮肤的变化进行了研究。组织学上，博来霉素治疗2周时就开始出现纤维化，且随着治疗时间的延长而加剧。生化方面，与对照组相比，在治疗期末，肺和皮肤中的总胶原蛋白和己糖胺含量显著增加。因此，该动物模型可方便地用于模拟人类疾病状况并测试有效的抗纤维化药物。
